Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 4/20 | 0.58 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.44 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP14 | P50281 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3659339 | 0.83 | FDPS (0.71) | FDPSGGPS1BTN3A1CA12CA2 | |
| Phosphonic Acid SCHEMBL10410285 | 0.77 | FDPS (0.63) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL515542 | 0.74 | FDPS (1.00) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL28381527 | 0.73 | FDPS (0.76) | FDPSGGPS1BTN3A1CA12CA2 | |
| Water SCHEMBL28274320 | 0.73 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL28380721 | 0.72 | FDPS (0.73) | FDPSGGPS1BTN3A1CA12CA2 | |
| Methyl Alcohol SCHEMBL9715289 | 0.71 | FDPS (0.93) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL10247560 | 0.70 | AGER (0.62) | FDPSCYP19A1 | |
| SCHEMBL6692428 | 0.70 | — | — | |
| SCHEMBL7667526 | 0.70 | FDPS (0.49) | FDPSCYP19A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1286665-B1 | TREATMENT REGIMEN OF INTRAVENOUS ZOLEDRONATE FOR THE TREATMENT OF BONE METABOLISM DISEASES | NOVARTIS AG (CH) | 2013-04-17 | — | — | EP | disclosed |
| US-8324189-B2 | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2012-12-04 | — | — | US | disclosed |
| CN-100389772-C | Use of zolendronate for mfg. medicament for treatment of bone metabolism diseases | NOVARTIS AG (CH) | 2008-05-28 | — | — | CN | disclosed |
| US-20070054885-A1 | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases | NOVARTIS PHARMACEUTICALS CORPORATION | 2007-03-08 | — | — | US | disclosed |
| CN-1481247-A | Use of zolendronate for mfg. medicament for treatment of bone metabolism diseases | 诺瓦提斯公司 | 2004-03-10 | — | — | CN | disclosed |
| US-20040014724-A1 | Method of administering a bisphosphonate | SEAMAN JOHN J (US) | 2004-01-22 | — | — | US | disclosed |
| EP-1286665-A2 | USE OF ZOLENDRONATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF BONE METABOLISM DISEASES | Novartis AG (CH) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001089494-A2 | USE OF ZOLENDRONATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF BONE METABOLISM DISEASES | NOVARTIS AG (CH) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054885-A1 | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases | BPGM, PHPT1, PPIP5K2 | FDPS 1050/4885GGPS1 285/4885BTN3A1 1044/4885 |
| US-20040014724-A1 | Method of administering a bisphosphonate | PTH1R, PPIP5K2, BPGM | FDPS 718/4885GGPS1 157/4885BTN3A1 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.